Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 4/20 | 0.39 |
| ▸ | METAP1 | P53582 | 3/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.35 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14019342 | 0.76 | METAP1 (0.61) | THRATHRBACHEMETAP1CYP19A1 | |
| SCHEMBL2424817 | 0.75 | METAP1 (0.65) | THRATHRBACHEMETAP1CYP19A1 | |
| SCHEMBL4858831 | 0.74 | THRA (0.58) | THRATHRBACHEMETAP1CYP19A1 | |
| SCHEMBL29130764 | 0.72 | METAP1 (0.64) | THRATHRBMETAP1CYP19A1CYP26A1 | |
| SCHEMBL5343888 | 0.71 | BAZ2B (0.47) | THRATHRBHTR2C | |
| SCHEMBL1853465 | 0.69 | ACHE (0.63) | ACHEMETAP1CYP19A1HTR2C | |
| SCHEMBL8028034 | 0.68 | METAP1 (0.64) | THRATHRBACHEMETAP1CYP19A1 | |
| SCHEMBL29130805 | 0.67 | METAP1 (0.68) | THRATHRBACHEMETAP1CYP19A1 | |
| SCHEMBL30715899 | 0.67 | METAP1 (0.68) | THRATHRBACHEMETAP1CYP19A1 | |
| SCHEMBL8030964 | 0.67 | MEN1 (0.44) | THRATHRBACHEMETAP1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432284-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20060041003-A1 | Estrogen receptor modulators | MERCK SHARP & DOHME LLC | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041003-A1 | Estrogen receptor modulators | GPER1, ESR2, ESR1 | THRA 406/4885THRB 584/4885ACHE 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.